Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
The oncologist（2023）
摘要
A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.
更多查看译文
关键词
metastatic breast cancer, human epidermal growth factor receptor 2 (HER2), trastuzumab, chemotherapy, targeted therapy, survivorship
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要